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Abstract: Polymorphic Human arylamine N-acetyltransferase (NAT2) inactivates the anti-tubercular drug isoniazid by acetyltransfer 
from acetylCoA. There are active NAT proteins encoded by homologous genes in mycobacteria including M. tuberculosis, M. bovis 
BCG, M. smegmatis and M. marinum. Crystallographic structures of NATs from M. smegmatis and M. marinum, as native enzymes and 
with isoniazid bound share a similar fold with the first NAT structure, Salmonella typhimurium NAT. There are three approximately 
equal domains and an active site essential catalytic triad of cysteine, histidine and aspartate in the first two domains. An acetyl group 
from acetylCoA is transferred to cysteine and then to the acetyl acceptor e.g. isoniazid. M. marinum NAT binds CoA in a more open 
mode compared with CoA binding to human NAT2. The structure of mycobacterial NAT may promote its role in synthesis of cell wall 
lipids, identified through gene deletion studies. NAT protein is essential for survival of M. bovis BCG in macrophage as are the proteins 
encoded by other genes in the same gene cluster (hsaA-D). HsaA-D degrade cholesterol, essential for mycobacterial survival inside 
macrophage. Nat expression remains to be fully understood but is co-ordinated with hsaA-D and other stress response genes in mycobac-
teria. 
Amide synthase genes in the streptomyces are also nat homologues. The amide synthases are predicted to catalyse intramolecular amide 
bond formation and creation of cyclic molecules, e.g. geldanamycin. Lack of conservation of the CoA binding cleft residues of M. 
marinum NAT suggests the amide synthase reaction mechanism does not involve a soluble CoA intermediate during amide formation and 
ring closure.  
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INTRODUCTION 
  The relationship between arylamine N-acetyltransferases and 
the mycobacteria has been established for many years [1]. The first 
identification of pharmacogenetic variation in the metabolism of 
isoniazid provided an immediate link with the mycobacteria as 
isoniazid is still the front line drug for treatment of tuberculosis 
[2,3].  
  NATs in bacteria were very important in establishing the active 
site catalytic triad as the mechanism whereby cysteine could be 
activated [4] to participate in transacetylation as the first stage in 
the reaction catalysed by arylamine N-acetyltransferases and cov-
ered elsewhere in this volume. The existence of the catalytic triad is 
essential for acetyltransferase activity in all organisms in which 
NAT has been found [5-9]. NATs and their homologues have now 
been characterized from a number of bacteria [10-15]. The NAT 
from Salmonella typhimurium was the first to be characterized both 
in terms of enzymic activity and three-dimensional structure [4,16-
18].  
NAT IN MYCOBACTERIA 
  Amongst the earliest bacterial NATs to be identified and char-
acterized at the structural level was the NAT from Mycobacterium 
smegmatis. The early work on mycobacterial nat genes co-incided 
with the completion of the genome of Mycobacterium tuberculosis 
the virulent laboratory strain H37Rv [19,20]. These studies have 
now been accompanied by the completion of many other mycobac-
terial genomes ([http://genolist.pasteur.fr/TubercuList/]). Through 
these and related studies ([http://www.tigr.org] [http://www.sanger. 
ac.uk/Projects/Microbes/]) it was identified that nat genes were 
present in a range of mycobacteria (Tables 1 and 2). From the stud-
ies of NATs which have been found in different mycobacteria, the 
level of similarity has been established and as for the other NAT 
sequence comparisons, the level of identity is least in the third 
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domain Fig. (1). So far mycobacterial nat genes have been identi-
fied in the slow growing mycobacteria including M. tuberculosis 
and also the non-pathogenic model strain Mycobacterium bovis 
BCG. A homologous gene is also present in the fast growers such 
as Mycobacterium smegmatis. In contrast, Mycobacterium leprae is 
missing a third of its genome including the nat gene and is unable 
to live outside cells.  
 The  nat genes from M. tuberculosis and M. bovis BCG are 
identical (Tables 1 and 2) and consequently the open reading 
frames are also identical (Table 2). It has been established that the 
nat gene is encoded in highly similar operons in M. bovis BCG and 
M. tuberculosis [21]. Interestingly this operon has been established 
to be essential for survival of M. tuberculosis within macrophage 
[22], as has the nat gene itself [23]. The NAT protein appears to 
play an important role in the synthesis of the mycobacterial cell 
wall in the slow growing mycobacteria and has been suggested to 
be a target for anti-mycobacterial therapy [23]. Interestingly, the 
operon appears to be upregulated following stress [24]. The precise 
role that the nat gene product plays in the stress response has not 
yet been established although a possibility for a metabolic role in 
relation to CoA intermediate homeostasis cannot be ruled out. Un-
derstanding the gene organization in different mycobacteria may 
help to unravel this role. 
nat GENES AND OPERON ORGANIZATION IN DIFFER-
ENT MYCOBACTERIAL SPECIES 
 The  nat gene was predicted to be part of an operon in most 
mycobacterial species [25]. The putative nat operon in M. tubercu-
losis H37Rv and in M. bovis BCG has been characterized to consist 
of six genes including nat [21] Fig. (2). The other genes encode the 
proteins known as HsaA, HsaD, HsaC, HsaB and there is also a 
pseudogene [21]. NAT protein has been found to be essential for 
survival of M. bovis BCG inside macrophage cells [23]. HsaA and 
HsaD are considered to play a part in cholesterol degradation [26], 
and cholesterol has now been shown to be an essential fuel for my-
cobacterial survival in host cells [27]. The genes of the operon are 
required for intracellular survival of M. tuberculosis in macro-NATs in Mycobacteria  Current Drug Metabolism, 2008, Vol. 9, No. 6    511 
Table 1.  Percent Conservation of Genes in Putative Nat-Containing Operon in M. tuberculosis H37Rv 
Rv3566a corresponds to a pseudogene, Rv3567c is thought to be hsaB and Rv3570c is thought to be hsaA
1. N/A = not applicable for comparison 
as sequence is not present. Bioinformatic resources were as follows: [http://genolist.pasteur.fr/TubercuList/] and [http://www.tigr.org] and 
[http://www.sanger.ac.uk/Projects/M_bovis/] 
Percent Conservation with M. tuberculosis H37Rv (%) 
Organisms Analysed 
Rv3566c (nat)  Rv3566a  Rv3567c  Rv3568c(hsaC)   Rv3569c (hsaD)  Rv3570c 
M. tuberculosis  CDC1551  100 100 100 100 100 100 
M. tuberculosis  Haarlem  100 100 100 100 100 100 
M. tuberculosis  F11  100 N/A 100 100 100 100 
M. tuberculosis C   100  N/A  98  100  100  99 
M. bovis BCG Pasteur  100  100  99.5  100  100  99.7 
M. bovis  AF2122/97  100  98.9 99 99.7  100  99.5 
M. marinum  M  75.4 N/A 90.5 90.7 89.9 90.9 
M. ulcerans  Agy99  75.8 N/A 89.9 90.7 89.5 90.6 
M. avium  K-10  67 N/A 88  89  89 90.6 
M. avium str.  104  68 N/A 88  89  89 90.6 
M. MCS  61 N/A 86  85  79  82 
M. KMS  61 N/A 86  85  79  82 
M. JLS  61 N/A 86  85  79  82 
M. smegmatis mc
2 155  60 N/A 81  82  80  81 
M. vanbaalenii  PYR-1  59 N/A 82  82  77  81 
M. gilvum  PYR-GCK  60 N/A 82  82  77  81 
Rhodococcus  RHA1  43 N/A 74  81  75  78 
1After [26]. 
 
 
Table 2.  Comparison of Amino Acid Sequence Amongst NAT Homologues in the Mycolata 
  The protein domains are based on the description in 
2. 
Percent Conservation with NAT from M. tuberculosis H37Rv (%) 
Domain  Organism 
1 2 3 
M .bovis AF2122/97  100  100  100 
M. bovis BCG Pasteur  100  100  100 
M. marinum  82  75  67 
M. ulcerans  82  75  67 
M. avium str.104  68  69  64 
M. avium K-10  68  68  64 
M.MCS  69  57  56 
M.KMS  69  57  56 
M.JLS  68  58  57 
M. smegmatis mc
2 155  62  61  56 
M. vanbaalenii PYR-1  59  55  60 
M. gilvum PYR-GCK  58  59  59 
Rhodococcus RHA1  50  45  33 
2See [20]. 
 
phages [22]. Investigation of the nat operon in different mycobacte-
ria will shed light on the function of the novel endogenous pathway 
encoded by these genes. The availability of the genome sequence 
from a number of mycobacteria, and the use of bioinformatic tools, 
has assisted the prediction and comparative analysis of the conser-
vation of the nat operon among mycobacteria (Table 1).  
  The gene organization around nat has been found to be almost 
identical in different strains of M. tuberculosis (Table 1), although 
no pseudogene appears to be present in the F11 or C strains. M. 
tuberculosis strain Haarlem showed 100% conservation of all genes 
in the cluster compared with H37Rv.  512    Current Drug Metabolism, 2008, Vol. 9, No. 6  Sim et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Comparison of the amino acid sequences of NATs from mycobacteria. 
A schematic diagram to show the amino acids which differ between MMNAT and TBNAT based on a ClustalW alignment (http://www.ebi.ac.uk/clustalw) and 
Espript [63]. The amino acids indicated above the bar are TBNAT residues and the amino acids indicated below the bar are MMNAT residues. White lines 
indicate residues which are a conserved substitution, grey lines indicate residues which are semi-conserved, black lines indicate residues which are non-
conservative and the dashes indicate deletions since MMNAT is shorter than TBNAT. The numbering is based on the TBNAT sequence. Amino acids are 
indicated by single letters.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Comparison of the operon organization of mycobacterial species.  
Operon analysis was carried out using the method described in [21] and also [31]. Genes have been named as they are annotated in the relevant genomes: nat = 
arylamine N-acetyltransferase; pseudo = pseudogene; hsa gene cluster is named as described in [21] and [26]; aspB is an aspartate aminotransferase; araC is 
homologous to the Escherichia coli transcription regulator [64]; deam/reduct refers to deaminase/reductase gene product; dh, dh1 and dh2 correspond to homo-
logues of dehydrogenase gene products; dhfr = dihydrofolate reductase. 
The nat genes in M. tuberculosis, M. bovis and M. smegmatis, and also hsaD and hsaC from M. tuberculosis and M. bovis encode proteins where enzyme activ-
ity has been confirmed. All of the open reading frames encode for putative proteins. 
See http://genolist.pasteur.fr/TubercuList/, http://www.tigr.org, http://www.sanger.ac.uk/Projects/Microbes/  NATs in Mycobacteria  Current Drug Metabolism, 2008, Vol. 9, No. 6    513 
 
 M.  bovis  and M. bovis BCG strains both show very high con-
servation of all of the operon genes in their genome. The conserva-
tion of each gene is above 98% and each strain also contains the 
pseudogene as in M. tuberculosis H37Rv.  
  Other mycobacterial species with a conserved organization 
around the nat gene are the Mycobacterium avium paratuberculosis 
K-10 and 104 strains. All of the homologous genes in these organ-
isms are highly conserved - above 80% with the exception of the 
nat gene which is only 67% for strain K-10 and 68% for strain 104, 
compared with H37Rv. The pseudogene is not present in M. avium 
strains.  
  In other mycobacterial strains, there appear to be separate gene 
clusters for the nat and hsa genes. Mycobacterium marinum and 
Mycobacterium ulcerans, the closest relatives phylogenetically to 
the M. tuberculosis complex [28] have a nat gene in close proxim-
ity to hsa genes. Although nat is separated from the homologues of 
the other genes found in the putative operon in M. tuberculosis 
H37Rv, the homologues hsaA, hsaD, hsaC, hsaB are adjacent to 
each other and in the same order as in M. tuberculosis H37Rv. This 
pattern of the four hsa genes being in an operon has been found in 
most mycobacterial species and also in the rhodococci which also 
have mycolic acids in their cell wall [26]. In addition the genes 
found between nat and the hsa gene clusters in M. marinum and M. 
ulcerans are highly conserved and are likely to encode for proteins 
with similar function [29,26 and references therein].  
  In the fast-growing soil-dwelling mycobacteria the pattern of 
the nat gene cluster differs. There are genes adjacent to nat, encod-
ing open reading frames with putative different function. The nat 
operon in M. smegmatis mc
2 155 is a putative three gene operon 
with nat being the first gene, followed by a gene that encodes for a 
transcriptional regulator belonging to the AraC/XylS protein fam-
ily, and a third gene annotated as encoding dihydrofolate reductase. 
The same pattern, but with the addition of two more genes has been 
found in Mycobacterium gilvum PYR-GCK and Mycobacterium 
vanbaalenii PYR-1. The additional genes in these latter two strains 
encode an acetyl-CoA dehydrogenase-like protein, based on ho-
mology, and a hypothetical protein. The three genes found in the 
Mycobacterium smegmatis mc
2 155 “nat operon” exist also in My-
cobacterium sp. KMS, MCS and JLS strains. The only difference is 
that the nat gene is separated by two more genes (encoding poten-
tial dehydrogenases) between nat and araC. In addition, the dihy-
drofolate reductase gene homologue is annotated in this genome as 
a bifunctional deaminase-reductase like protein (Table 1, Fig. (2)). 
  There is clearly variation of the nat gene clusters amongst my-
cobacteria and work requires to be done to establish unequivocally 
the nature of the proteins encoded. We can distinguish three differ-
ent operon patterns. In slow-growing and most pathogenic myco-
bacteria, including M. tuberculosis H37Rv, the nat  and the hsa 
genes forming one operon. In the relatively faster growing patho-
genic close relatives such as M. ulcerans and M. marinum the nat 
gene cluster is relatively close to the hsa genes, whereas in the fast 
growing environmental non-pathogenic mycobacteria, nat belongs 
to a different gene cluster distinct from that in slow-growers, Fig. 
(2).  
  Although the control of gene expression patterns in mycobacte-
ria is not well understood, it is likely to be at the transcriptional 
level [30]. There are about 190 transcription regulatory proteins 
annotated in the genome of M. tuberculosis [19]. There are single, 
multiple and overlapping, as well as alternative internal promoters 
in the genome that play an important role in the transcription of a 
single gene or operon [31]. The “nat operon” in M. tuberculosis is 
part of the kstR regulon (stress regulon) that is involved in the lipid 
metabolism [24]. The same study showed that the hsa gene cluster 
(Fig. (2)) seems to belong to the kstR regulon in M. smegmatis mc
2  
 
155, a fast growing organism where the nat gene is part of a distinct 
gene cluster. However, the transcriptional control recognition motif 
is present upstream of the nat gene as well as upsteam of the hsa 
gene cluster in M. smegmatis, suggesting that at least under certain 
conditions  nat  and  hsa  genes are co-ordinately regulated in M. 
smegmatis even though they are in different operons.  
  Studying the organization and different components of the op-
erons in which nat genes are found will help to understand the roles 
of nat and the associated genes in mycobacteria and in actinomy-
cetales. 
GENETIC MODIFICATION AND IDENTIFICATION OF 
POLYMORPHISMS 
  In order to understand the role of the nat gene in mycobacteria, 
experiments were carried out on genetically modified strains 
[20,32,23]. Investigation of possible polymorphisms in nat genes in 
clinical isolates of M. tuberculosis were also investigated [33-35].  
Initially, the main interest was that the nat gene product might have 
a role in isoniazid resistance in M. tuberculosis since it was known 
that human NAT2 metabolised isoniazid to the therapeutically inac-
tive form N-acetylisoniazid [36,37]. Effectively isoniazid is a pro-
drug and it was considered that if isoniazid were acetylated within 
mycobacterial cells that it would not be activated by the katG gene 
product. The activated isoniazid inhibits the synthesis of mycolic 
acids [38]. In order to test this hypothesis, initially it was important 
to identify whether the nat gene was expressed in M. tuberculosis. 
It was clearly demonstrated that the nat gene was transcribed and 
also that protein was present in cytosols of growing organisms 
which could be detected with specific antisera against M. tubercu-
losis NAT [32]. The NAT protein was active in acetylation of 
isoniazid [33]. These studies confirmed that the nat gene product 
was transcribed and active in M. tuberculosis and M. bovis BCG. 
Other studies confirmed that the same is true of the nat gene prod-
uct in M. smegmatis [20,25,32]. The NAT enzyme from M. smeg-
matis was demonstrated to be able to metabolise isoniazid and 
when the nat gene from M. smegmatis was overexpressed in M. 
bovis BCG the susceptibility of the slow growing mycobacterium to 
isoniazid was decreased as would be expected [20].  
  The corollary experiment in which the nat gene is deleted was 
carried out in M. bovis BCG [23] and also M. smegmatis [32]. In 
these studies the sensitivity to isoniazid was increased by up to 
three fold.  
  Investigations of clinically isolated strains of M. tuberculosis 
identified point mutations in the nat gene [33,35]. The mutations 
which were found resulted in the substitution of an arginine residue 
in place of a glycine residue at position 207 [33] and this mutation 
was accompanied by a second mutation in some clinical strains in 
which a tyrosine at position 177 is replaced by a histidine (compare 
Fig. (1). The effect of the Y177H mutation has not been determined 
directly using recombinant protein studies but recombinant NAT 
protein from M. tuberculosis showed that the G207R mutation re-
sulted in a NAT enzyme with very poor activity [33]. A corre-
sponding mutation introduced into NAT from M. smegmatis, does 
not have such a deleterious effect on enzymic activity [34].  
  Each of the mutations in nat was restricted to the same family 
of clinical isolates of M. tuberculosis [35]. There was no clear cor-
relation between these loss-of-function mutations and isoniazid 
sensitivity, although it would be expected that mutations resulting 
in loss of function of NAT would improve sensitivity to isoniazid. 
It was concluded that NAT appears to modulate the effects of other 
known genetic factors on isoniazid sensitivity of strains of M. tu-
berculosis, but NAT activity it is not directly correlated with isoni-
azid resistance. A gain of function mutation would be required to 
induce isoniazid resistance.  
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NAT APPEARS TO PLAY AN ENDOGENOUS ROLE IN 
MYCOBACTERIA 
  The clinical isolates were considered to belong to strain fami-
lies which grow particularly slowly [35], although growth of slow 
growing mycobacteria can be temperamental in vitro.  
 When  the  nat gene was deleted in M. smegmatis [32] and also 
in  M. bovis BCG, there were interesting findings suggesting an 
endogenous role for the NAT enzyme. This has been reviewed ex-
tensively [39] and so will be covered in summary here. The growth 
of the nat deleted strains of both M. bovis BCG and M. smegmatis 
was shown to be delayed. In M. bovis BCG, it was noted that the 
ultrastructure and susceptibility to antibiotics was altered. The or-
ganisms became more susceptible to antibiotics such as gentamycin 
to which they were normally resistant [23]. It was also noted that 
the characteristic mycobacterial cell wall lipid components were not 
present in the nat deleted strain of M. bovis BCG but complementa-
tion with nat restored the wild type phenotype. These studies sug-
gested that nat has either a direct or an indirect role in cell wall 
lipid metabolism. It still remains to be determined whether the nat 
gene product affects lipid metabolism directly or whether it inter-
feres with metabolic energy production and reducing equivalents 
essential for cell wall lipid synthesis. One important feature of these 
studies was the demonstration that the nat gene is essential for sur-
vival of M. bovis BCG within macrophage. As stated above, this is 
also true of the other genes which have been identified in the same 
operon [22]. 
  Specific NAT inhibitors have been identified through high 
throughput screening of chemical libraries [40,41] and through 
investigating natural products [42] using the mycobacterial NAT 
enzymes as targets. These studies have clearly shown that inhibition 
of NAT activity in M. bovis BCG has very similar effects to delet-
ing the nat gene. Inhibitors of the other genes in the operon [21] 
which are essential for survival of M. tuberculosis in macrophage 
have been demonstrated to affect the cell wall lipid composition in 
a similar fashion to lack of NAT activity [21]. Recently these genes 
have been suggested to have a role in cholesterol degradation [26]. 
Since it now appears that cholesterol is essential as a fuel for myco-
bacteria inside macrophage [27], it is looking increasingly likely 
that NAT has a role in intermediary metabolism and energy produc-
tion in mycobacteria inside macrophage but this still needs to be 
investigated. 
STRUCTURAL STUDIES 
  The NAT proteins encoded by nat genes from M. bovis BCG 
and M. tuberculosis are identical (Tables 1 & 2) and although small 
amounts have been obtained for analytical purposes, insufficient 
has been generated to allow a full structural characterization [33, 
presented data
3].  
  The sequences of NATs from a range of mycobacteria and my-
colata have been compared (Table 2) and sequence conservation is 
very high in all of these proteins in the first two domains but less 
highly conserved in the third domain (Table 2). In view of the small 
amount of M. tuberculosis NAT protein available to date, NAT 
from other mycobacterial sources has been used for structural stud-
ies. NAT from M. smegmatis and NAT from the organism M. 
marinum [43] which is being used as a model for M. tuberculosis 
have been investigated. M. marinum, as the name suggests, infects 
fish and frogs. The mycobacterial NATs which have been generated 
in mg quantities as recombinant proteins have been compared in 
relation to their substrate specificity profiles [43]. The specificity 
profile of M. marinum is very similar to NAT from M. smegmatis 
except that p-aminobenzoic acid and procainamide are poorer sub-
strates for the NAT enzyme from M. marinum.  
                                                 
3 Sikora, A. L. and Blanchard, J. S. (2008). Kinetic mechanism and characterization of 
arylamine N-acetyltransferase from Mycobacterium tuberculosis. 235th ACS National 
Meeting, New Orleans, LA, USA. 
  The structure of the NAT from M. smegmatis [44] was the first 
structure of a mycobacterial NAT enzyme to be obtained and the 
active site catalytic triad is superimposable on the structure of the 
enzyme from S. typhimurium [4] (Fig. (3)).  
  The amino acids which interact with isoniazid as substrate at 
the active site have been identified through structure determination 
following co-crystallisation with both M. marinum NAT and with 
NAT from M. smegmatis (Fig. (4)). The main residues interacting 
with isoniazid are entirely conserved in these two proteins (Fig. 
(1)). The structure of NAT from M. smegmatis does not differ sig-
nificantly between the structure with isoniazid bound and the struc-
ture of the enzyme alone [7]. The same is true of the NAT enzyme 
from M. marinum [43]. However, when the structure of the NAT 
enzyme from M. marinum was solved, it was clear that there were 
two binding sites for isoniazid, one was the same as the active site 
identified in M. smegmatis NAT, but the other was at a more ex-
posed surface site. This second site was subsequently shown to 
correspond to the binding site of the adenine rings in Coenzyme A 
through a co-crystallisation study of NAT from M. marinum with 
CoA [43]. 
  At around the time that these studies were being done, the struc-
ture of a human NAT enzyme with CoA bound was also obtained 
[9]. The binding sites for CoA in these two enzymes are clearly 
distinct Fig. (5). There have been discussions of the loop region 
which is present in eukaryotic NAT enzymes between the second 
and third domains but which is missing in the prokaryotic enzymes 
[25,45,46]. It has been demonstrated that the loop and also the C-
terminus of the human enzyme is folded across the active site cleft 
[9]. The C-terminus has been demonstrated to be important in de-
termining the activity of the NAT from S. typhimurium [17] and 
also in contributing to specificity of different mammalian isoen-
zymes [45,47] along with the region around residue 124-129 in the 
mammalian NAT structures [48,9]. The differences in binding of 
CoA to human NAT2 and to M. marinum NAT (Fig. (5)) are likely 
to result from the interactions with the loop and the C-terminus of 
the human enzyme which partly occludes the active site cleft (Fig. 
(5)) [43,49]. 
  It has been discussed that the difference in the CoA binding to 
mycobacterial and human NAT is an evolutionary snap-shot [43]. 
What is unclear is whether the difference in binding represents the 
different roles that these enzymes play in their respective organ-
isms. 
BACTERIAL NAT HOMOLOGUES CATALYZING AMIDE 
SYNTHESIS 
  Many Streptomyces and related species contain genes homolo-
gous to the nat genes. These genes encode amide synthase
4 en-
zymes which catalyse a ring-closure reaction to yield a large macro-
cyclic compound (Fig. (6)). Compounds produced are antibacterial, 
for example Rifamycin from Amycolatopsis mediterranei [50], or 
anti-tumour activity, such as Ansamitocin from Actinosynnema 
pretiosum [51,52]. 
  The genes encoding the amide synthase enzymes are commonly 
found at the end of a gene cluster encoding Polyketide Synthase 
enzymes [53-57]. These enzymes build up a large chain in a step-
wise manner [58,59]. The amide synthetase enzyme joins the amine 
end of the chain to the carbonyl which has been attached to an acyl 
carrier protein enzyme, forming the amide bond, as shown in Fig. 
(6).  
  Whilst there has been much analysis of the polyketide synthase 
enzymes within these gene clusters responsible for the growing acyl 
chain [54,59,55,60] the enzymes responsible for ring closure which 
are homologous to the NAT enzymes have been studied to a lesser 
extent. RifF, from the Rifamycin producing bacterium A. 
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Fig. (3). Overlay of the crystal structures of NATs from bacteria.  
NATs from M. smegmatis (pdb code 1gx3), S. typhimurium (pdb code 1e2t), P. aeruginosa (pdb code 1w4f) and M. loti NAT1 (pdb code 2bsz) are shown 
superimposed, each in a different grey tone. The active site triad residues are shown in ball and stick representation and are indicated by arrows. After [13]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Interactions of isoniazid with the active site of NAT from M. smegmatis.  
The interactions are shown using Ligplot analysis [65]. Inh1 (E) indicates isoniazid. The residues are indicated by their numbers in M. smegmatis NAT. After 
[7]. An identical Ligplot for M. marinum NAT is found in [43]. 
 
mediterranei, has been investigated and recombinant enzyme has 
been produced [14]. Based on homology modelling, it was pro-
posed that the amide synthase RifF would share the same fold as 
that of the NAT enzymes due to the high sequence similarity [14]. 
To date, no crystallographic structure of this family of enzymes 
homologous to the NAT enzymes exists.  
  Overall, the amide synthase enzymes show similarity with the 
NAT enzymes (Fig. (7)). The catalytic triad of residues Cys – His – 
Asp is completely conserved, one of the more obvious differences 
is that in the NAT enzymes, the PFENL motif (very highly con-
served in NATs) is not conserved in the amide synthase enzymes. 
The amide synthase enzymes have a common sequence of PYD** 
in place of the PFENL motif. Several residues which have been 
identified as essential for NAT activity (Arg 9 and Arg 64) [61] are 
again not completely conserved in the amide synthase enzymes. 
Leu 24 has been proposed to be essential for stability of the protein 
due to its interaction with Leu 79 and Val 112 [62], these residues 
being conserved across the NAT and amide synthetase enzymes.516    Current Drug Metabolism, 2008, Vol. 9, No. 6  Sim et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Comparison of the interaction of CoA with NAT from M. marinum and human NAT2. 
Molecular surface representations of M. marinum NAT with CoA bound (pdb 2vfc) (A) with human NAT2 with CoA bound (pdb 2pfr) (B). The CoA is shown 
in ball and stick representation. Ribbon representation of the binding of M marinum NAT (MMNAT) with CoA bound (dark ribbon) compared with CoA 
bound to human NAT2(hNAT2) (light ribbon). The structures have been overlaid and the CoA molecules are shown in ball and stick representation, as are the 
residues of the active site triad (Cys indicated by an arrow) (C). Frame (D) shows the location of isoniazid in the active site, in relation to the position of CoA 
in the structure of M. marinum NAT. Isoniazid and CoA are shown in ball and stick representation and the active site resides are just visible, with Cys being 
indicated by an arrow. After [43].  
 
Arg 155 appears to play a role in stabilising the beta barrel domain. 
Pro 133 is also conserved between the amide synthase and NAT 
enzymes, possibly contributing towards the conformation of the 
loop in which it is situated. Additionally, Tyr 190 is completely 
conserved amongst all enzymes and is situated proximal to the cata-
lytic Asp 122. This residue may play a role in holding the Asp 122 
residue in position, maintaining the conformation of the catalytic 
triad. Numbering is corresponding to [62]. 
  Whilst there are many similarities in the sequences between the 
NAT enzymes and the amide synthetase enzymes, there are likely 
to be subtle differences in the structures of the two enzymes just as 
observed between NATs from different species [12,43,9]. Recent 
publications have described the mode of binding of CoenzymeA to 
the prokaryotic M. marinum NAT [43] and human NAT2 [9]. The 
residues involved in CoA binding are not well conserved in the 
amide synthases. It is likely that given there are two distinct modes 
of CoA binding to the NAT enzymes, that there will be differences 
in ligand binding in the amide synthase enzymes. Comparison of 
the residues involved in CoA binding in the NAT enzymes, with the 
amide synthase enzymes shows that the necessary residues are not 
conserved across in the amide synthases. It is likely therefore that 
there could be an entirely novel mode of binding of ligands within 
the amide synthetase active site. Given that there are likely to be 
interactions between the polyketide synthase enzymes and the am-
ide synthases encoded by the gene clusters, protein:protein interac-
tions may play a part in understanding how these enzymes carry outNATs in Mycobacteria  Current Drug Metabolism, 2008, Vol. 9, No. 6    517 
A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). The reactions leading to the synthesis of Geldanamycin by amide ring closure.  
A. The series of biosynthetic reactions in Streptomyces leading to biosynthesis of the benzoquinone ansamycin geldanamycin. B. the ring closure reaction cata-
lysed by an amide synthetase is highlighted. (After [58,59]). AHBA is amino hydroxybenzoic acid. The amide synthetase is encoded by the gene gdmf. The 
earlier genes in the cluster are numbered alphabetically. PKS is polyketide synthetase. 518    Current Drug Metabolism, 2008, Vol. 9, No. 6  Sim et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Alignment of putative Amide Synthetase protein sequences.  
The sequences of the putative amide synthetases are shown in comparison with human NAT1 (P50295) and NAT from Mycobacterium smegmatis (086309). 
The essential residues as indicated are after [61]. The amide synthetases listed are as follows: O52547|RIFF_AMYMD 3-amino-5-hydroxybenzoic acid syn-
thase - Amycolatopsis mediterranei (Nocardia mediterranei)., A8M6D1|A8M6D1_9ACTO N-acetyltransferase - Salinispora arenicola , 
Q2PC63|Q2PC63_STRAH Putative amide synthase - Streptomyces achromogenes subsp. Rubradiris, Q84G21|Q84G21_STRHY GdmF - Streptomyces hygro-
scopicus, Q1L0S9|Q1L0S9_STRHY GelD - Streptomyces hygroscopicus subsp. Duamyceticus, A8LFZ8|A8LFZ8_9ACTO N-acetyltransferase - Frankia sp. 
EAN1pec., A4FDM9|A4FDM9_SACEN 3-amino-5-hydroxybenzoic acid synthase - Saccharopolyspora erythraea (strain NRRL 23338), 
Q8KUF7|Q8KUF7_ACTPA Amide synthase - Actinosynnema pretiosum subsp. auranticum., Q848C2|Q848C2_STRHY Amide synthase - Streptomyces hy-
groscopicus (sequence cropped @ N-term to remove cloning artifacts)., Q0PLZ9|Q0PLZ9_9ACTO Putative N-acetyltransferase - Kitasatospora putterlickiae., 
Q8GNN3|Q8GNN3_STRHY ShnN - Streptomyces hygroscopicus., Q1L0S3|Q1L0S3_STRHY NapF - Streptomyces hygroscopicus subsp. duamyceticus. 
 
their ring closure reaction. This is a good example of divergent 
evolution where a similar protein fold can carry out multiple func-
tions.  
  The NAT field is ripe to begin to answer the questions on the 
mycobacterial NATs and the amide synthetases with the availability 
of physical and genetic techniques, identifying the importance of a 
multi-disciplinary approach embracing systems biology as well as 
molecular analytical techniques to understand biology. 
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